Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy
1. Sitagliptin demonstrated the most prominent malignancy-related safety signal among the dipeptidyl peptidase-4 inhibitors studied. Evidence Rating Level: 2 (Good) ...



![Type I diabetes not associated with early menopause [OVADIA study]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/diabetes1_edited-350x250.jpg)
![Engineered stem cells mitigate liver damage caused by radiation [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/Human_embryonic_stem_cells-350x250.png)

